{
    "Trade/Device Name(s)": [
        "GlucoSure Voice Blood Glucose Monitoring System",
        "Contrex Plus Glucose Control Solution"
    ],
    "Submitter Information": "Apex BioTechnology Corp.",
    "510(k) Number": "K073137",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062799"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "NBW",
        "JJX"
    ],
    "Summary Letter Date": "February 04, 2008",
    "Summary Letter Received Date": "February 15, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "POCT"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "GlucoSure Voice meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for GlucoSure Voice Blood Glucose Monitoring System with voice functionality and alternate site testing for quantitative glucose measurement.",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood from fingertip, forearm, or palm for monitoring diabetes mellitus in lay users and healthcare professionals; meter includes voice functionality for visually impaired users.",
    "fda_folder": "Clinical Chemistry"
}